aTyr Pharma
ATYR
50 hedge funds and large institutions have $143M invested in aTyr Pharma in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
0% more funds holding
Funds holding: 50 → 50 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
6% less capital invested
Capital invested by funds: $152M → $143M (-$9.08M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.86M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.27M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$1.26M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$266K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$260K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.74M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.75M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$1.71M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$694K |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$528K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PI
51
Putnam Investments
Boston,
Massachusetts
| – | -$528K | -3,674 | Closed |
|
|
PAM
52
Panagora Asset Management
Boston,
Massachusetts
| – | -$61K | -423 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$12K | -87 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -24 | Closed |
|
55
Acadian Asset Management
Boston,
Massachusetts
| – | -$2K | -12 | Closed |
|
56
Wells Fargo
San Francisco,
California
| – | -$142 | -1 | -50% |
|
ATYR Hedge Fund Activity: Q4 2015 in Review
50 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2015, worth a combined $143M — down 6% from $152M a quarter earlier.
Fund positioning in ATYR was balanced in Q4 2015: 6 funds opened new positions, 6 closed out, 20 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.86M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.74M sold.
- 50 institutional investors held aTyr Pharma (ATYR) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $143M of aTyr Pharma stock for Q4 2015, down 6% quarter-over-quarter.
- 6 funds opened new aTyr Pharma positions in Q4 2015 and 6 closed out, a net change of 0 holders.
- The largest aTyr Pharma buyer in Q4 2015 was BlackRock Fund Advisors, an estimated $2.86M added.
- The largest aTyr Pharma seller in Q4 2015 was Deerfield Management, an estimated $4.74M sold.
Based on aggregated 13F filings for Q4 2015.